News Summary

9Bio Therapeutics, a Québec City-based biotech startup, is leveraging an AI-guided structural biology platform to design cancer therapies that target tumours while sparing healthy tissues. Co-founded by Philipe Gobeil, the company aims to address the toxic side effects associated with current cancer treatments. 9Bio plans to ‘resurrect’ clinically validated therapies that failed due to toxicity, offering new hope for patients by ensuring treatments only affect tumours. The startup utilizes a multidisciplinary team and has developed partnerships with organizations like the National Research Council Canada and Merck Digital Science Studios to further its research. Since its inception in June 2023, 9Bio has demonstrated proof of concept and is advancing its therapies into animal testing, aiming to improve patient quality of life while accelerating the development process in the oncology space.